.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,674,711

« Back to Dashboard

Claims for Patent: 5,674,711

Title: Heteropolymeric protein production methods
Abstract:Cultured mammalian cells transfected with new vectors comprising full-length or partial .alpha. and .beta. subunit genomic DNA sequences produce significantly higher levels of dimeric glycoprotein hormone than do cells transfected with .alpha. and .beta. subunit cDNA sequences. In cases where only the cDNA clones are available, the cDNA sequences can be used in new expression vectors comprising introns or other important genomic regions from a homologous or heterologous source.
Inventor(s): Kelton; Christie A. (Hopkinton, MA), Nugent; Noreen P. (Framingham, MA), Chappel; Scott C. (Boston, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:08/095,853
Patent Claims: 1. A method for the production of a dimeric protein selected from the group consisting of luteinizing hormone, follicle stimulating hormone, chorionic gonadotropin and thyroid stimulating hormone, comprising:

a) providing a first vector comprising a promoter, a structural gene encoding the .alpha.-subunit of said dimeric protein, and a terminating sequence, said promoter, structural gene and terminating sequence being operatively linked to permit expression of said gene when a host cell is appropriately transformed by said first vector, wherein said structural gene comprises a coding region and at least one intron, wherein one intron is immediately 5' to the coding region of the .alpha.-subunit, with the proviso that the structural gene encoding the .alpha.-subunit is not the entire genomic sequence of the gene encoding the .alpha.-subunit of bovine luteinizing hormone;

b) providing a structural gene encoding the .beta.-subunit of said dimeric protein, said .beta.-subunit structural gene being within said first vector containing said .alpha.-subunit and being operatively linked thereto so as to permit expression of said .beta.-subunit structural gene when a host cell is appropriately transformed by said first vector, or in a second vector comprising a promoter, said .beta.-subunit structural gene and a terminating sequence, said promoter, .beta.-subunit structural gene and terminating sequence being operatively linked to permit expression of said .beta.-subunit structural gene when a host cell is appropriately transformed by said second vector;

c) transforming host cells with said first vector or, if said structural gene encoding the .beta.-subunit is in said second vector, transforming host cells with said first and second vectors; and

d) culturing said transformed cells under conditions by which the dimeric protein is produced,

wherein said intron immediately 5' to the coding region of the .alpha.-subunit is spatially disposed with respect to the ATG of the coding region such that an amount of dimeric protein is produced which is greater than that which can be produced under comparable conditions using a structural gene encoding the .alpha.-subunit which is the cDNA without introns.

2. The method of claim 1 wherein said structural gene encoding said .beta.-subunit is the genomic sequence of the gene encoding said .beta.-subunit.

3. The method of claim 1 wherein said structural gene encoding said .alpha.-subunit comprises a DNA encoding said .alpha.-subunit to which has been added a plurality of introns, 3' and 5' flanking regions, endogenous 5' untranslated sequence and polyadenylation signal.

4. The method of claim 1 wherein said dimeric protein is human follicle stimulating hormone and said first vector comprises the genomic sequence of the gene encoding said .alpha.-subunit.

5. The method of claim 1 wherein said dimeric protein is human luteinizing hormone and said first vector comprises the genomic sequence of the gene encoding said .alpha.-subunit.

6. The method of claim 1 wherein said dimeric protein is human chorionic gonadotropin hormone and said first vector comprises the genomic sequence of the gene encoding said .alpha.-subunit.

7. The method of claim 1 wherein said dimeric protein is non-human chorionic gonadotropin hormone and said first vector comprises the genomic sequence of the gene encoding said .alpha.-subunit.

8. The method of claim 2 wherein said dimeric protein is non-human follicle stimulating hormone and said vector comprises the genomic sequence of the gene encoding said .alpha.-subunit.

9. The method of claim 1 wherein said .alpha.-subunit comprises the sequence

Met Asp Tyr Tyr Arg Lys Tyr Ala Ala Ile Phe Leu Val Thr Leu Ser Val Phe Leu His Val Leu His Ser Ala Pro Asp Val Gln Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu Val Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu Asn His Thr Ala Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser.

10. The method of claim 4 wherein said .beta.-subunit comprises the sequence

Met Lys Thr Leu Gln Phe Phe Phe Leu Phe Cys Cys Trp Lys Ala Ile Cys Cys Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu Lys Glu Glu Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala Gly Tyr Cys Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro Lys Ile Gln Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val Arg Val Pro Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro Val Ala Thr Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met Lys Glu.

11. A method in accordance with claim 1 wherein said structural gene encoding the .alpha.-subunit is other the entire genomic sequence of the gene encoding said .alpha.-subunit.

12. A method in accordance with claim 1 wherein said structural gene encoding the .beta.-subunit is in said second vector.

13. A method in accordance with claim 1 wherein said structural gene encoding the .beta.-subunit includes at least one intron.

14. A method in accordance with claim 1 wherein, in the structural gene encoding the .alpha.-subunit, said one intron which is immediately 5' to the coding region of the .alpha.-subunit naturally occurs in the genomic sequence of the gene encoding the .alpha.-subunit of the natural dimeric protein corresponding to the dimeric protein being produced.

15. The method of claim 1 wherein said dimeric protein is human thyroid stimulating hormone and said first vector comprises the genomic sequence of the gene encoding said .alpha.-subunit.

16. A method in accordance with claim 1, wherein said structural gene contains only a single intron.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc